Lakeside Advisors INC. bought a new position in shares of Pfizer Inc. (NYSE: PFE – Get Rating) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,512 shares of the biopharmaceutical company stock, valued at approximately $ 325,000.
Several other hedge funds have also modified their holdings of PFE. MJP Associates Inc. ADV grew its holdings in Pfizer by 18.9% during the 4th quarter. MJP Associates Inc. ADV now owns 19,458 shares of the biopharmaceutical company stock valued at $ 1,102,000 after buying an additional 3,096 shares during the last quarter. Harrison & Co Wealth Management LLC purchased a new position in shares of Pfizer during the 4th quarter worth $ 1,455,000. Capital Advisors Inc. OK lifted its stake in shares of Pfizer by 3.9% during the 4th quarter. Capital Advisors Inc. OK now owns 541,381 shares of the biopharmaceutical company stock worth $ 31,969,000 after purchasing an additional 20,514 shares during the period. Xponance Inc. lifted its stake in shares of Pfizer by 25.3% during the 4th quarter. Xponance Inc. now owns 521,138 shares of the biopharmaceutical company stock worth $ 30,773,000 after purchasing an additional 105,259 shares during the period. Finally, Summit Trail Advisors LLC lifted its stake in shares of Pfizer by 9.9% during the 3rd quarter. Summit Trail Advisors LLC now owns 26,752 shares of the biopharmaceutical company stock worth $ 1,151,000 after purchasing an additional 2,400 shares during the period. 66.50% of the stock is owned by institutional investors and hedge funds.
PFE has been the topic of several research reports. Morgan Stanley initiated coverage on Pfizer in a research report on Wednesday, April 6th. They issued an “equal weight” rating and a $ 55.00 target price on the stock. JPMorgan Chase & Co. set a $ 57.00 target price on Pfizer in a research report on Tuesday, May 3rd. Berenberg Bank set a $ 50.00 target price on Pfizer in a research report on Friday, May 27th. Wells Fargo & Company cut their target price on Pfizer from $ 60.00 to $ 55.00 in a research report on Wednesday, May 4th. Finally, SVB Leerink initiated coverage on Pfizer in a research report on Monday, May 23rd. They issued a “market perform” rating and a $ 55.00 target price on the stock. Nine research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $ 57.26.
In related news, EVP William R. Carapezzi, Jr. sold 32,908 shares of Pfizer stock in a transaction dated Thursday, May 12th. The stock was sold at an average price of $ 50.00, for a total value of $ 1,645,400.00. Following the completion of the transaction, the executive vice president now directly owns 38,146 shares in the company, valued at $ 1,907,300. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Jennifer B. Damico sold 4,000 shares of Pfizer stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $ 50.50, for a total value of $ 202,000.00. Following the completion of the transaction, the senior vice president now owns 15,064 shares of the company stock, valued at $ 760,732. The disclosure for this sale can be found here. Insiders have sold 41,126 shares of company stock valued at $ 2,075,003 over the last 90 days. Insiders own 0.05% of the company stock.
Shares of Pfizer stock opened at $ 46.53 on Friday. The business has a 50-day moving average of $ 50.90 and a 200-day moving average of $ 52.34. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.39 and a quick ratio of 1.13. The company has a market capitalization of $ 261.07 billion, a PE ratio of 10.67, a P / E / G ratio of 0.59 and a beta of 0.76. Pfizer Inc. has a 1-year low of $ 38.70 and a 1-year high of $ 61.71.
Pfizer (NYSE: PFE – Get Rating) last announced its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $ 1.62 earnings per share for the quarter, missing the estimate consensus of $ 1.66 by ($ 0.04). The business had revenue of $ 25.66 billion for the quarter, compared to analyst estimates of $ 24.73 billion. Pfizer had a net margin of 26.97% and a return on equity of 38.29%. The firm’s revenue was up 76.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $ 0.93 earnings per share. On average, equities analysts expect that Pfizer Inc. will post 6.62 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, June 10th. Stockholders of record on Friday, May 13th were paid a dividend of $ 0.40 per share. The ex-dividend date was Thursday, May 12th. This represents a $ 1.60 annualized dividend and a dividend yield of 3.44%. Pfizer’s dividend payout ratio is presently 36.70%.
Pfizer Profile: (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE: PFE – Get Rating).
Receive News & Ratings for Pfizer Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.